Global Gene Therapy On Cardiovascular Disease Market Research Report 2026

Gene Therapy On Cardiovascular Disease Market

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery. Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.

Market Driver: The increasing prevalence of cardiovascular diseases (CVDs) worldwide is a major driver for the gene therapy market in this area. As traditional treatments, such as surgery, medications, and lifestyle changes, sometimes fail to offer long-term solutions, gene therapy presents a promising alternative. By targeting the root causes of CVDs at the genetic level, gene therapy offers the potential for more effective and durable treatments. Advancements in gene editing technologies, such as CRISPR, have further accelerated the development of gene therapies for cardiovascular diseases, allowing for precise modification of genes that regulate heart function, blood vessel health, and inflammation. This technological progress, combined with the growing demand for personalized and innovative treatments, is driving the market forward.Market Challenge: Despite its potential, the gene therapy market for cardiovascular diseases faces several challenges, including high development costs and the complexity of clinical trials. Developing safe and effective gene therapies requires significant investment in research and long-term testing, which can delay the availability of these therapies to patients. Additionally, regulatory approval for gene therapies can be slow and uncertain, creating barriers to rapid commercialization. Moreover, there are concerns regarding the long-term safety and potential unintended genetic consequences of modifying human DNA, which may limit widespread adoption. The complexity of delivering gene therapies to the cardiovascular system, such as targeting specific cells or tissues without causing adverse effects, remains a significant technical challenge.

Global key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%.

This report delivers a comprehensive overview of the global Gene Therapy On Cardiovascular Disease market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Gene Therapy On Cardiovascular Disease. The Gene Therapy On Cardiovascular Disease market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Gene Therapy On Cardiovascular Disease market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Gene Therapy On Cardiovascular Disease manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Gene Therapy On Cardiovascular Disease Market Report

Chapter Outline

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Viral Gene Therapy

1.2.3 Non-Viral Gene Therapy

1.3 Market by Application

1.3.1 Global Gene Therapy On Cardiovascular Disease Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Heart Disease

1.3.3 Vascular Disease

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2.1 Global Gene Therapy On Cardiovascular Disease Market Perspective (2021–2032)

2.2 Global Gene Therapy On Cardiovascular Disease Growth Trends by Region

2.2.1 Global Gene Therapy On Cardiovascular Disease Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Gene Therapy On Cardiovascular Disease Historic Market Size by Region (2021–2026)

2.2.3 Gene Therapy On Cardiovascular Disease Forecasted Market Size by Region (2027–2032)

2.3 Gene Therapy On Cardiovascular Disease Market Dynamics

2.3.1 Gene Therapy On Cardiovascular Disease Industry Trends

2.3.2 Gene Therapy On Cardiovascular Disease Market Drivers

2.3.3 Gene Therapy On Cardiovascular Disease Market Challenges

2.3.4 Gene Therapy On Cardiovascular Disease Market Restraints

3.1 Global Top Gene Therapy On Cardiovascular Disease Players by Revenue

3.1.1 Global Top Gene Therapy On Cardiovascular Disease Players by Revenue (2021–2026)

3.1.2 Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Players (2021–2026)

3.2 Global Top Gene Therapy On Cardiovascular Disease Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Gene Therapy On Cardiovascular Disease Revenue

3.4 Global Gene Therapy On Cardiovascular Disease Market Concentration Ratio

3.4.1 Global Gene Therapy On Cardiovascular Disease Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy On Cardiovascular Disease Revenue in 2025

3.5 Global Key Players of Gene Therapy On Cardiovascular Disease Head Offices and Areas Served

3.6 Global Key Players of Gene Therapy On Cardiovascular Disease, Products and Applications

3.7 Global Key Players of Gene Therapy On Cardiovascular Disease, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4.1 Global Gene Therapy On Cardiovascular Disease Historic Market Size by Type (2021–2026)

4.2 Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Type (2027–2032)

5.1 Global Gene Therapy On Cardiovascular Disease Historic Market Size by Application (2021–2026)

5.2 Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Application (2027–2032)

6.1 North America Gene Therapy On Cardiovascular Disease Market Size (2021–2032)

6.2 North America Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Gene Therapy On Cardiovascular Disease Market Size by Country (2021–2026)

6.4 North America Gene Therapy On Cardiovascular Disease Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7.1 Europe Gene Therapy On Cardiovascular Disease Market Size (2021–2032)

7.2 Europe Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Gene Therapy On Cardiovascular Disease Market Size by Country (2021–2026)

7.4 Europe Gene Therapy On Cardiovascular Disease Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8.1 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size (2021–2032)

8.2 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Region (2021–2026)

8.4 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9.1 Latin America Gene Therapy On Cardiovascular Disease Market Size (2021–2032)

9.2 Latin America Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Gene Therapy On Cardiovascular Disease Market Size by Country (2021–2026)

9.4 Latin America Gene Therapy On Cardiovascular Disease Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size (2021–2032)

10.2 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country (2021–2026)

10.4 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11.1 Renovacor

11.1.1 Renovacor Company Details

11.1.2 Renovacor Business Overview

11.1.3 Renovacor Gene Therapy On Cardiovascular Disease Introduction

11.1.4 Renovacor Revenue in Gene Therapy On Cardiovascular Disease Business (2021–2026)

11.1.5 Renovacor Recent Development

11.2 Gene Biotherapeutics

11.2.1 Gene Biotherapeutics Company Details

11.2.2 Gene Biotherapeutics Business Overview

11.2.3 Gene Biotherapeutics Gene Therapy On Cardiovascular Disease Introduction

11.2.4 Gene Biotherapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2021–2026)

11.2.5 Gene Biotherapeutics Recent Development

11.3 AskBio

11.3.1 AskBio Company Details

11.3.2 AskBio Business Overview

11.3.3 AskBio Gene Therapy On Cardiovascular Disease Introduction

11.3.4 AskBio Revenue in Gene Therapy On Cardiovascular Disease Business (2021–2026)

11.3.5 AskBio Recent Development

11.4 Human Stem Cells Institute

11.4.1 Human Stem Cells Institute Company Details

11.4.2 Human Stem Cells Institute Business Overview

11.4.3 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Introduction

11.4.4 Human Stem Cells Institute Revenue in Gene Therapy On Cardiovascular Disease Business (2021–2026)

11.4.5 Human Stem Cells Institute Recent Development

11.5 Novartis

11.5.1 Novartis Company Details

11.5.2 Novartis Business Overview

11.5.3 Novartis Gene Therapy On Cardiovascular Disease Introduction

11.5.4 Novartis Revenue in Gene Therapy On Cardiovascular Disease Business (2021–2026)

11.5.5 Novartis Recent Development

11.6 Biogen

11.6.1 Biogen Company Details

11.6.2 Biogen Business Overview

11.6.3 Biogen Gene Therapy On Cardiovascular Disease Introduction

11.6.4 Biogen Revenue in Gene Therapy On Cardiovascular Disease Business (2021–2026)

11.6.5 Biogen Recent Development

11.7 Gilead Sciences

11.7.1 Gilead Sciences Company Details

11.7.2 Gilead Sciences Business Overview

11.7.3 Gilead Sciences Gene Therapy On Cardiovascular Disease Introduction

11.7.4 Gilead Sciences Revenue in Gene Therapy On Cardiovascular Disease Business (2021–2026)

11.7.5 Gilead Sciences Recent Development

11.8 Sarepta Therapeutics

11.8.1 Sarepta Therapeutics Company Details

11.8.2 Sarepta Therapeutics Business Overview

11.8.3 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Introduction

11.8.4 Sarepta Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2021–2026)

11.8.5 Sarepta Therapeutics Recent Development

11.9 Alnylam Pharmaceuticals

11.9.1 Alnylam Pharmaceuticals Company Details

11.9.2 Alnylam Pharmaceuticals Business Overview

11.9.3 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Introduction

11.9.4 Alnylam Pharmaceuticals Revenue in Gene Therapy On Cardiovascular Disease Business (2021–2026)

11.9.5 Alnylam Pharmaceuticals Recent Development

11.10 Amgen

11.10.1 Amgen Company Details

11.10.2 Amgen Business Overview

11.10.3 Amgen Gene Therapy On Cardiovascular Disease Introduction

11.10.4 Amgen Revenue in Gene Therapy On Cardiovascular Disease Business (2021–2026)

11.10.5 Amgen Recent Development

11.11 Spark Therapeutics

11.11.1 Spark Therapeutics Company Details

11.11.2 Spark Therapeutics Business Overview

11.11.3 Spark Therapeutics Gene Therapy On Cardiovascular Disease Introduction

11.11.4 Spark Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2021–2026)

11.11.5 Spark Therapeutics Recent Development

11.12 Akcea Therapeutics

11.12.1 Akcea Therapeutics Company Details

11.12.2 Akcea Therapeutics Business Overview

11.12.3 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Introduction

11.12.4 Akcea Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2021–2026)

11.12.5 Akcea Therapeutics Recent Development

11.13 Sunway Biotech

11.13.1 Sunway Biotech Company Details

11.13.2 Sunway Biotech Business Overview

11.13.3 Sunway Biotech Gene Therapy On Cardiovascular Disease Introduction

11.13.4 Sunway Biotech Revenue in Gene Therapy On Cardiovascular Disease Business (2021–2026)

11.13.5 Sunway Biotech Recent Development

11.14 SIBIONO

11.14.1 SIBIONO Company Details

11.14.2 SIBIONO Business Overview

11.14.3 SIBIONO Gene Therapy On Cardiovascular Disease Introduction

11.14.4 SIBIONO Revenue in Gene Therapy On Cardiovascular Disease Business (2021–2026)

11.14.5 SIBIONO Recent Development

11.15 AnGes

11.15.1 AnGes Company Details

11.15.2 AnGes Business Overview

11.15.3 AnGes Gene Therapy On Cardiovascular Disease Introduction

11.15.4 AnGes Revenue in Gene Therapy On Cardiovascular Disease Business (2021–2026)

11.15.5 AnGes Recent Development

11.16 Orchard Therapeutics

11.16.1 Orchard Therapeutics Company Details

11.16.2 Orchard Therapeutics Business Overview

11.16.3 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Introduction

11.16.4 Orchard Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2021–2026)

11.16.5 Orchard Therapeutics Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

List of Tables

 Table 1. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

 Table 2. Key Players of Viral Gene Therapy

 Table 3. Key Players of Non-Viral Gene Therapy

 Table 4. Global Gene Therapy On Cardiovascular Disease Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

 Table 5. Global Gene Therapy On Cardiovascular Disease Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

 Table 6. Global Gene Therapy On Cardiovascular Disease Market Size by Region (US$ Million), 2021–2026

 Table 7. Global Gene Therapy On Cardiovascular Disease Market Share by Region (2021–2026)

 Table 8. Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Region (US$ Million), 2027–2032

 Table 9. Global Gene Therapy On Cardiovascular Disease Market Share by Region (2027–2032)

 Table 10. Gene Therapy On Cardiovascular Disease Market Trends

 Table 11. Gene Therapy On Cardiovascular Disease Market Drivers

 Table 12. Gene Therapy On Cardiovascular Disease Market Challenges

 Table 13. Gene Therapy On Cardiovascular Disease Market Restraints

 Table 14. Global Gene Therapy On Cardiovascular Disease Revenue by Players (US$ Million), 2021–2026

 Table 15. Global Gene Therapy On Cardiovascular Disease Market Share by Players (2021–2026)

 Table 16. Global Top Gene Therapy On Cardiovascular Disease Players by Tier (Tier 1, Tier 2, and Tier 3), based on Gene Therapy On Cardiovascular Disease Revenue, 2025

 Table 17. Ranking of Global Top Gene Therapy On Cardiovascular Disease Companies by Revenue (US$ Million) in 2025

 Table 18. Global 5 Largest Players Market Share by Gene Therapy On Cardiovascular Disease Revenue (CR5 and HHI), 2021–2026

 Table 19. Global Key Players of Gene Therapy On Cardiovascular Disease, Headquarters and Area Served

 Table 20. Global Key Players of Gene Therapy On Cardiovascular Disease, Products and Applications

 Table 21. Global Key Players of Gene Therapy On Cardiovascular Disease, Date of General Availability (GA)

 Table 22. Mergers and Acquisitions, Expansion Plans

 Table 23. Global Gene Therapy On Cardiovascular Disease Market Size by Type (US$ Million), 2021–2026

 Table 24. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2021–2026)

 Table 25. Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Type (US$ Million), 2027–2032

 Table 26. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2027–2032)

 Table 27. Global Gene Therapy On Cardiovascular Disease Market Size by Application (US$ Million), 2021–2026

 Table 28. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2021–2026)

 Table 29. Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Application (US$ Million), 2027–2032

 Table 30. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2027–2032)

 Table 31. North America Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

 Table 32. North America Gene Therapy On Cardiovascular Disease Market Size by Country (US$ Million), 2021–2026

 Table 33. North America Gene Therapy On Cardiovascular Disease Market Size by Country (US$ Million), 2027–2032

 Table 34. Europe Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

 Table 35. Europe Gene Therapy On Cardiovascular Disease Market Size by Country (US$ Million), 2021–2026

 Table 36. Europe Gene Therapy On Cardiovascular Disease Market Size by Country (US$ Million), 2027–2032

 Table 37. Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

 Table 38. Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Region (US$ Million), 2021–2026

 Table 39. Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Region (US$ Million), 2027–2032

 Table 40. Latin America Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

 Table 41. Latin America Gene Therapy On Cardiovascular Disease Market Size by Country (US$ Million), 2021–2026

 Table 42. Latin America Gene Therapy On Cardiovascular Disease Market Size by Country (US$ Million), 2027–2032

 Table 43. Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

 Table 44. Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country (US$ Million), 2021–2026

 Table 45. Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country (US$ Million), 2027–2032

 Table 46. Renovacor Company Details

 Table 47. Renovacor Business Overview

 Table 48. Renovacor Gene Therapy On Cardiovascular Disease Product

 Table 49. Renovacor Revenue in Gene Therapy On Cardiovascular Disease Business (US$ Million), 2021–2026

 Table 50. Renovacor Recent Development

 Table 51. Gene Biotherapeutics Company Details

 Table 52. Gene Biotherapeutics Business Overview

 Table 53. Gene Biotherapeutics Gene Therapy On Cardiovascular Disease Product

 Table 54. Gene Biotherapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (US$ Million), 2021–2026

 Table 55. Gene Biotherapeutics Recent Development

 Table 56. AskBio Company Details

 Table 57. AskBio Business Overview

 Table 58. AskBio Gene Therapy On Cardiovascular Disease Product

 Table 59. AskBio Revenue in Gene Therapy On Cardiovascular Disease Business (US$ Million), 2021–2026

 Table 60. AskBio Recent Development

 Table 61. Human Stem Cells Institute Company Details

 Table 62. Human Stem Cells Institute Business Overview

 Table 63. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product

 Table 64. Human Stem Cells Institute Revenue in Gene Therapy On Cardiovascular Disease Business (US$ Million), 2021–2026

 Table 65. Human Stem Cells Institute Recent Development

 Table 66. Novartis Company Details

 Table 67. Novartis Business Overview

 Table 68. Novartis Gene Therapy On Cardiovascular Disease Product

 Table 69. Novartis Revenue in Gene Therapy On Cardiovascular Disease Business (US$ Million), 2021–2026

 Table 70. Novartis Recent Development

 Table 71. Biogen Company Details

 Table 72. Biogen Business Overview

 Table 73. Biogen Gene Therapy On Cardiovascular Disease Product

 Table 74. Biogen Revenue in Gene Therapy On Cardiovascular Disease Business (US$ Million), 2021–2026

 Table 75. Biogen Recent Development

 Table 76. Gilead Sciences Company Details

 Table 77. Gilead Sciences Business Overview

 Table 78. Gilead Sciences Gene Therapy On Cardiovascular Disease Product

 Table 79. Gilead Sciences Revenue in Gene Therapy On Cardiovascular Disease Business (US$ Million), 2021–2026

 Table 80. Gilead Sciences Recent Development

 Table 81. Sarepta Therapeutics Company Details

 Table 82. Sarepta Therapeutics Business Overview

 Table 83. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product

 Table 84. Sarepta Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (US$ Million), 2021–2026

 Table 85. Sarepta Therapeutics Recent Development

 Table 86. Alnylam Pharmaceuticals Company Details

 Table 87. Alnylam Pharmaceuticals Business Overview

 Table 88. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product

 Table 89. Alnylam Pharmaceuticals Revenue in Gene Therapy On Cardiovascular Disease Business (US$ Million), 2021–2026

 Table 90. Alnylam Pharmaceuticals Recent Development

 Table 91. Amgen Company Details

 Table 92. Amgen Business Overview

 Table 93. Amgen Gene Therapy On Cardiovascular Disease Product

 Table 94. Amgen Revenue in Gene Therapy On Cardiovascular Disease Business (US$ Million), 2021–2026

 Table 95. Amgen Recent Development

 Table 96. Spark Therapeutics Company Details

 Table 97. Spark Therapeutics Business Overview

 Table 98. Spark Therapeutics Gene Therapy On Cardiovascular Disease Product

 Table 99. Spark Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (US$ Million), 2021–2026

 Table 100. Spark Therapeutics Recent Development

 Table 101. Akcea Therapeutics Company Details

 Table 102. Akcea Therapeutics Business Overview

 Table 103. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product

 Table 104. Akcea Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (US$ Million), 2021–2026

 Table 105. Akcea Therapeutics Recent Development

 Table 106. Sunway Biotech Company Details

 Table 107. Sunway Biotech Business Overview

 Table 108. Sunway Biotech Gene Therapy On Cardiovascular Disease Product

 Table 109. Sunway Biotech Revenue in Gene Therapy On Cardiovascular Disease Business (US$ Million), 2021–2026

 Table 110. Sunway Biotech Recent Development

 Table 111. SIBIONO Company Details

 Table 112. SIBIONO Business Overview

 Table 113. SIBIONO Gene Therapy On Cardiovascular Disease Product

 Table 114. SIBIONO Revenue in Gene Therapy On Cardiovascular Disease Business (US$ Million), 2021–2026

 Table 115. SIBIONO Recent Development

 Table 116. AnGes Company Details

 Table 117. AnGes Business Overview

 Table 118. AnGes Gene Therapy On Cardiovascular Disease Product

 Table 119. AnGes Revenue in Gene Therapy On Cardiovascular Disease Business (US$ Million), 2021–2026

 Table 120. AnGes Recent Development

 Table 121. Orchard Therapeutics Company Details

 Table 122. Orchard Therapeutics Business Overview

 Table 123. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product

 Table 124. Orchard Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (US$ Million), 2021–2026

 Table 125. Orchard Therapeutics Recent Development

 Table 126. Research Programs/Design for This Report

 Table 127. Key Data Information from Secondary Sources

 Table 128. Key Data Information from Primary Sources

 Table 129. Authors List of This Report

List of Figures

 Figure 1. Gene Therapy On Cardiovascular Disease Picture

 Figure 2. Global Gene Therapy On Cardiovascular Disease Market Size Comparison by Type (US$ Million), 2021–2032

 Figure 3. Global Gene Therapy On Cardiovascular Disease Market Share by Type: 2025 vs 2032

 Figure 4. Viral Gene Therapy Features

 Figure 5. Non-Viral Gene Therapy Features

 Figure 6. Global Gene Therapy On Cardiovascular Disease Market Size by Application (US$ Million), 2021–2032

 Figure 7. Global Gene Therapy On Cardiovascular Disease Market Share by Application: 2025 vs 2032

 Figure 8. Heart Disease Case Studies

 Figure 9. Vascular Disease Case Studies

 Figure 10. Gene Therapy On Cardiovascular Disease Report Years Considered

 Figure 11. Global Gene Therapy On Cardiovascular Disease Market Size (US$ Million), Year-over-Year: 2021–2032

 Figure 12. Global Gene Therapy On Cardiovascular Disease Market Size, (US$ Million), 2021 vs 2025 vs 2032

 Figure 13. Global Gene Therapy On Cardiovascular Disease Market Share by Region: 2025 vs 2032

 Figure 14. Global Gene Therapy On Cardiovascular Disease Market Share by Players in 2025

 Figure 15. Global Gene Therapy On Cardiovascular Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

 Figure 16. The Top 10 and 5 Players Market Share by Gene Therapy On Cardiovascular Disease Revenue in 2025

 Figure 17. North America Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 18. North America Gene Therapy On Cardiovascular Disease Market Share by Country (2021–2032)

 Figure 19. United States Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 20. Canada Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 21. Europe Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 22. Europe Gene Therapy On Cardiovascular Disease Market Share by Country (2021–2032)

 Figure 23. Germany Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 24. France Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 25. U.K. Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 26. Italy Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 27. Russia Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 28. Ireland Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 29. Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 30. Asia-Pacific Gene Therapy On Cardiovascular Disease Market Share by Region (2021–2032)

 Figure 31. China Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 32. Japan Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 33. South Korea Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 34. Southeast Asia Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 35. India Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 36. Australia & New Zealand Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 37. Latin America Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 38. Latin America Gene Therapy On Cardiovascular Disease Market Share by Country (2021–2032)

 Figure 39. Mexico Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 40. Brazil Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 41. Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 42. Middle East & Africa Gene Therapy On Cardiovascular Disease Market Share by Country (2021–2032)

 Figure 43. Israel Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 44. Saudi Arabia Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 45. UAE Gene Therapy On Cardiovascular Disease Market Size YoY Growth (US$ Million), 2021–2032

 Figure 46. Renovacor Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2021–2026)

 Figure 47. Gene Biotherapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2021–2026)

 Figure 48. AskBio Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2021–2026)

 Figure 49. Human Stem Cells Institute Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2021–2026)

 Figure 50. Novartis Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2021–2026)

 Figure 51. Biogen Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2021–2026)

 Figure 52. Gilead Sciences Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2021–2026)

 Figure 53. Sarepta Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2021–2026)

 Figure 54. Alnylam Pharmaceuticals Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2021–2026)

 Figure 55. Amgen Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2021–2026)

 Figure 56. Spark Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2021–2026)

 Figure 57. Akcea Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2021–2026)

 Figure 58. Sunway Biotech Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2021–2026)

 Figure 59. SIBIONO Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2021–2026)

 Figure 60. AnGes Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2021–2026)

 Figure 61. Orchard Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2021–2026)

 Figure 62. Bottom-up and Top-down Approaches for This Report

 Figure 63. Data Triangulation

 Figure 64. Key Executives Interviewed